Leronlimab (anti-CCR5)

Synonyms: PRO 140; Vyrologix

Catalog No.A2040 Purity: 99%

Leronlimab (anti-CCR5) （PRO 140; Vyrologix）is a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy. It is being investigated as a potential therapy in the treatment of HIV infection.

Click to purchase the isotype control of Leronlimab (anti-CCR5)

Purity & Quality Control

Batch: Purity: 99% Protein concentration: 3.19mg/ml Endotoxin Level: ＜1EU/mg

Choose Selective CCR Inhibitors

Biological Activity

Description	Leronlimab (anti-CCR5) （PRO 140; Vyrologix）is a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy. It is being investigated as a potential therapy in the treatment of HIV infection.

In Vitro
In vitro	Leronlimab binds CCR5 in multiple breast cancer cell lines, reducing ligand-induced Ca^+ 2 signaling, invasion of TNBC into Matrigel, and transwell migration, also enhances the breast cancer (BCa) cell killing of the BCa chemotherapy reagent, doxorubicin.^[1]
Cell Research:	Equal numbers of cells were plated, and after 72 h of exposure to the drugs, cells were incubated with 1 mg/mL of MTT for 90 min. The reduced (insoluble and colored) formazan was dissolved in 0.04 N HCl acidified isopropanol and measured spectrophotometrically at 570 nm.

In Vitro

In vitro

Leronlimab binds CCR5 in multiple breast cancer cell lines, reducing ligand-induced Ca^+ 2 signaling, invasion of TNBC into Matrigel, and transwell migration, also enhances the breast cancer (BCa) cell killing of the BCa chemotherapy reagent, doxorubicin.^[1]

Cell Research:

Equal numbers of cells were plated, and after 72 h of exposure to the drugs, cells were incubated with 1 mg/mL of MTT for 90 min. The reduced (insoluble and colored) formazan was dissolved in 0.04 N HCl acidified isopropanol and measured spectrophotometrically at 570 nm.

In Vivo
In vivo	In xenografts conducted with Nu/Nu mice, leronlimab reduces lung metastasis of the TNBC cell line, MB-MDA-231, reducing the metastatic tumor burden of established TNBC lung metastasis.^[1]
Animal Research	AnimalModels:Female NCI Athymic nu/nu nude mice injected with MB-MDA-231 cells expressing Luc2-eGFP Dosages:2 mg/mouse Administration:i.p.^[1]

In Vivo

In vivo

In xenografts conducted with Nu/Nu mice, leronlimab reduces lung metastasis of the TNBC cell line, MB-MDA-231, reducing the metastatic tumor burden of established TNBC lung metastasis.^[1]

Animal Research

AnimalModels:Female NCI Athymic nu/nu nude mice injected with MB-MDA-231 cells expressing Luc2-eGFP
Dosages:2 mg/mouse
Administration:i.p.^[1]

References
[1] Jiao X, et al. Breast Cancer Res. 2021 Jan 23;23(1):11.

References

[1] Jiao X, et al. Breast Cancer Res. 2021 Jan 23;23(1):11.

Product Details

CAS No.	674782-26-4
Molecular Weight	146.7 KD
Isotype	Human IgG4
Application	Leronlimab (anti-CCR5)
Sterility	0.2 μM filtered
Formulation	PBS Buffer, PH 7.4
Storage (From the date of receipt)	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles.

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field